Comparative Pharmacology
Head-to-head clinical analysis: NEO POLYCIN versus PREDNICEN M.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO POLYCIN versus PREDNICEN M.
NEO-POLYCIN vs PREDNICEN-M
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis. Polymyxin B is a polypeptide antibiotic that disrupts bacterial cell membrane permeability by interacting with phospholipids. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier.
Prednicen-M is a glucocorticoid that binds to the glucocorticoid receptor (GR), leading to altered gene expression. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production (e.g., IL-1, IL-2, TNF-alpha). It also induces lipocortin synthesis, which inhibits arachidonic acid release.
Apply a thin layer to the affected area 3 to 4 times daily. Use a unit-dose ointment or eye drops: 1 to 2 drops in the affected eye(s) every 4 to 6 hours, or more frequently as needed.
Oral, 5-60 mg/day divided every 6-12 hours, adjusted based on disease severity and response.
None Documented
None Documented
Neomycin: 2-3 hours in patients with normal renal function; prolonged to 12-24 hours in renal impairment. Polymyxin B: 6-8 hours. Bacitracin: 1.5 hours (if absorbed); typically not systemically available.
2-3 hours (prednisone); terminal half-life of prednisolone is 2-4 hours in normal renal function, prolonged to 3-4 hours in renal impairment, and may be extended in hepatic impairment.
Neomycin: ~30-50% of absorbed dose excreted renally as unchanged drug; unabsorbed drug eliminated fecally. Polymyxin B: minimal renal excretion (<1% of dose); primarily eliminated via non-renal routes, possibly biliary or metabolic. Bacitracin: negligible renal excretion after topical use; systemic absorption minimal.
Renal: ~80% as metabolites and unchanged drug (primarily as 17-ketosteroids and glucuronide conjugates); fecal: <5%; biliary: minor.
Category C
Category C
Antibiotic Combination
Ophthalmic Corticosteroid/Antibiotic Combination